In the first series of experiments we tested whether commonly used FDA-approved drugs for multiple sclerosis GA (CopaxoneTM) and IFN-β (BetaseronTM) affected platelet functions as determined by measurement of thrombin-induced Ca2+ influx, an established hallmark of platelet activation. This evidence concerns the gene IFNB1 and multiple sclerosis.